Utilization and factors precluding the initiation of consolidative durvalumab in unresectable stage III non-small cell lung cancer

Durvalumab after concurrent chemoradiation has significantly improved survival in stage III non-small cell lung cancer (NSCLC). However, there is limited data evaluating the utilization and challenges to deliver durvalumab consolidation in the real world. We assessed the use of consolidative durvalu...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Radiother Oncol
Autores principales: Shaverdian, Narek, Offin, Michael D., Rimner, Andreas, Shepherd, Annemarie F., Wu, Abraham J., Rudin, Charles M., Hellmann, Matthew D., Chaft, Jamie E., Gomez, Daniel R.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2019
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7523024/
https://ncbi.nlm.nih.gov/pubmed/31786421
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.radonc.2019.11.015
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares